Efficacy and safety of a triple combination of atezolizumab, bevacizumab plus GEMOX for advanced biliary tract cancer: a multicenter, single-arm, retrospective study.
Kang WangZong-Han LiuHong-Ming YuYu-Qiang ChengYan-Jun XiangJing-Ya ZhongQian-Zhi NiLi-Ping ZhouChao LiangHong-Kun ZhouWei-Wei PanWei-Xing GuoJie ShiShu-Qun ChengPublished in: Therapeutic advances in gastroenterology (2023)
The triple combination of atezolizumab, bevacizumab, and GEMOX may be efficacious and safe for patients with advanced BTC. ALS2CL may be a potential predictive biomarker for the efficacy of triple combination therapy.